Antibody neutralization of coronaviruses

SARS-CoV-2是一种阳性单链RNA病毒，于2019年12月首次分离到。感染SARS-CoV-2会导致一种临床综合征--冠状病毒诱导的疾病-19型(新冠肺炎)，其特征是发热、咳嗽和呼吸急促，可迅速发展为需要机械通气的呼吸和心力衰竭。自那以后，几乎所有国家和地区都受到了影响。迅速实施和部署有效的SARS-CoV-2疫苗有可能减少感染的有害影响，特别是在脆弱人群中，遏制传播，并结束大流行。抗体被认为有助于预防SARS-CoV-2感染和新冠肺炎。保护性抗体反应的特异性和机制尚未确定，将在本项目中进行探索。

SARS-CoV-2 is a positive-sense single-stranded RNA virus first isolated in December of 2019. SARS-CoV-2 infection results in a clinical syndrome, coronavirus-induced disease-19 (COVID-19), which is characterized by fever, cough, and shortness of breath that can progress rapidly to respiratory and cardiac failure requiring mechanical ventilation. Virtually all countries and territories have since been affected. Rapid implementation and deployment of an effective SARS-CoV-2 vaccine has the potential to lessen the deleterious effects of infection, especially in vulnerable populations, curb transmission, and end the pandemic. Antibodies are hypothesized to contribute to protection from SARS-CoV-2 infection and COVID-19. The specificities and mechanisms of a protective antibody response have not been established and will be explored in this project.